THE MAIN CAUSES OF FIBROADENOMA DEVELOPMENT IN YOUNG GIRLS UNDER THE CONDITIONS OF UZBEKISTAN
Keywords:
fibroadenoma, young women, breast tumors, hormonal imbalance, endemic goiter, estrogen/progesterone ratio, prolactin, iodine deficiency, reproductive health.Abstract
Fibroadenoma represents the most common benign breast tumor affecting young women. In recent decades, breast disorders, particularly non-malignant tumors, have increasingly influenced women’s health worldwide. Among these conditions, fibroadenoma predominates, especially in adolescents and young adults. Reports from different studies indicate that fibroadenomas account for approximately 50–70% of all benign breast lesions. Although the highest prevalence is observed between the ages of 15 and 25, the tumor may occur from childhood through the menopausal period. The high frequency of fibroadenoma in young women highlights its importance, as it has implications for reproductive health, emotional well-being, and future maternal potential. According to the World Health Organization (WHO) and the American Cancer Society (ACS), the incidence is estimated at 1.5–2% among females younger than 20, increasing to 8–10% by the age of 25. Epidemiological data from Uzbekistan demonstrate that nearly 7–9% of women aged 18–25 are diagnosed with fibroadenoma. These findings underline the clinical and public health significance of this condition.
References
1. Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO. Morphologic and immunohistochemical analysis of breast fibroadenoma and its variants. Histopathology. 2007;51(2):223–34.
2. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations. Am J Hum Genet. 2003;72(5):1117–30.
3. Buzdar AU. Role of endocrine therapy in benign breast disease. Endocr Relat Cancer. 2001;8(1):47–54.
4. Buzdar AU. Role of endocrine therapy in the management of hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2013;11(4):535–42.
5. Carty NJ, Carter C, Rubin C, Ravichandran D, Royle GT, Taylor I. Management of fibroadenoma of the breast. Ann R Coll Surg Engl. 1995;77(2):127–30.
6. Dutta M, Jaiswal R, Srinivasan R. Fibroadenoma of the breast: clinical, pathological and radiological correlation. Indian J Surg Oncol. 2019;10(1):25–30.
7. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146–51.
8. Ece B, Karaca L, Ünlü E, Çetin B, Özmen V. Imaging of fibroadenoma: Be careful with imaging follow-up. Molecular and Clinical Oncology. 2022;17(13):115. doi:10.3892/mco.2022.2584
9. El-Wakeel H, Umpleby HC. Systematic review of fibroadenoma as a risk factor for breast cancer. Breast. 2003;12(5):302–7.
10. Greenberg R, Skornick Y, Kaplan O. Management of breast fibroadenomas. J Gen Intern Med. 1998;13(9):640–45.
11. Guray M, Sahin A. A. Benign breast diseases: classification, diagnosis, and management. Oncologist. 2006;11(5):435–49.
12. Holbrook AI, Newell MS. Update on benign breast disease and risk of breast cancer. Semin Roentgenol. 2011;46(4):269–75.
13. Kuijper A, Mommers EC, van der Wall E, van Diest PJ. Histopathology of fibroadenoma of the breast. Am J Clin Pathol. 2001;115(5):736–42.
14. Kurbanov S, Rakhimova M, Karimova N. Epidemiology and clinical characteristics of fibroadenoma in young women in Uzbekistan. Tashkent Med J. 2020;4(12):55–63.
15. Lambertini M, Moore HC, Leonard RCF, Loibl S, Munster P, Bruzzone M, et al. GnRH agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient–level data. J Clin Oncol. 2018;36(5):1981–99.
16. McDivitt RW, Stevens JA, Lee NC. Histologic types of benign breast disease and the risk for breast cancer. Cancer. 1992;69(6):1408–14.
17. Memon W, Rahman M, Parveen S. Association between iodine deficiency disorders and benign breast disease in young women. J Pak Med Assoc. 2002;52(7):174–7.
18. Mourouti N, Kontogianni MD, Papavagelis C, Plytzanopoulou P, Vassilakou T, Psaltopoulou T. Reproductive and lifestyle factors in relation to benign breast disease: a case–control study. Maturitas. 2015;81(8):265–9.
19. Rosen PP. Fibroepithelial neoplasms. In: Rosen’s Breast Pathology. 3rd ed. Lippincott Williams & Wilkins; 2009. p. 187–210.
20. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 2006;102(1–5):89–96.
21. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. 2005;353(2,3):275–85.
22. Soto AM, Sonnenschein C. Environmental causes of cancer: endocrine disruptors as carcinogens. Nat Rev Endocrinol. 2010;6(7):363–70.
23. Turken O, Narin Y, Demirbas S, et al. Breast fibroadenoma and thyroid diseases: a clinical correlation. Breast J. 2003;9(5):427–30.
24. Wu YT, Chen ST, Chen CJ, Kuo YL, Tseng LM, Chen DR. Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy. World J Surg Oncol. 2014;12:335. doi:10.1186/1477-7819-12-335
